is indicated for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is a two-drug combination of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF).

Manufactured by: Gilead Sciences, Inc.

Active Ingredient(s): Emtricitabine and Tenofovir Alafenamide

Dosage Form:  Film coated Tablets, Oral

Strength:  Each tablet contains 200 mg of Emtricitabine and 25 mg Tenofovir Alafenamide. 

FDA approved: April 4, 2016

More information about Descovy:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208215s000lbl.pdf

http://www.gilead.com/~/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf?la=en